Efficacy and tolerability of add-on lacosamide in children with Lennox-Gastaut syndrome

Acta Neurologica Scandinavica

Volumn 129, Issue 6, 2014, Pages 420-424

  Grosso, S ^a   Coppola, G ^b   Cusmai, R ^c   Parisi, P ^d   Spalice, A ^d   Foligno, S ^d   Verrotti, A ^e   Balestri, P ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Antiepileptic drugs; Drug resistant epilepsy; Epileptic encephalopathy; Paediatrics; Seizures

Indexed keywords

HARKOSERIDE; ACETAMIDE DERIVATIVE; ANTICONVULSIVE AGENT;

ADD ON THERAPY; ADOLESCENT; ANTICONVULSANT THERAPY; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; LENNOX GASTAUT SYNDROME; MALE; NAUSEA; TREATMENT OUTCOME; VOMITING; WALKING DIFFICULTY; CLINICAL TRIAL; DRUG COMBINATION; FOLLOW UP; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; RETROSPECTIVE STUDY; TIME;

ACETAMIDES; ADMINISTRATION, ORAL; ADOLESCENT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LENNOX GASTAUT SYNDROME; MALE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84897957566     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12221     Document Type: Article

References (25)

1. Arzimanoglou A, French J, Blume WT et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol 2009;8:82-93.
2. Genton P, Guerrini R, Dravet C. The Lennox-Gastaut syndrome. In: H Meinardi, ed. Handbook of clinical neurology: the epilepsies, Part II. Amsterdam: Elsevier, 2000;211-222.
3. Fattore C, Perucca E. Novel medications for epilepsy. Drugs 2011;71:2151-78.
4. Cawello W, Boekens H, Bonn R. Absorption, disposition, metabolic fate and elimination of the anti-epileptic drug lacosamide in humans: mass balance following intravenous and oral administration. Eur J Drug Metab Pharmacokinet 2012;37:241-8.
5. Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007;48:1308-17.
6. Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009;50:443-53.
7. Chung SS. New treatment option for partial-onset seizures: efficacy and safety of lacosamide. Ther Adv Neurol Disord 2010;3:77-83.
8. Chung S, Sperling MR, Biton V et al. Lacosamide as adjunctive therapy for partial onset seizures: a randomized controlled trial. Epilepsia 2010;51:958-967.
9. Commission on Classification Terminology of the International League. Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22:489-501.
10. Commission on Classification Terminology of the International League. Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-99.
11. Gavatha M, Ionnou I, Papavasiliou AS. Efficacy and tolerability of oral lacosamide as adjunctive therapy in pediatric patients with pharmacoresistant focal epilepsy. Epilepsy Behav 2011;20:691-3.
12. Guilhoto LM, Loddenkemper T, Gooty VD et al. Experience with lacosamide in a series of children with drug-resistant focal epilepsy. Pediatr Neurol 2011;44:414-9.
13. Heyman E, Lahat E, Levin N, Berkovitch M, Gandelman-Marton R. Preliminary efficacy and safety of lacosamide in children with refractory epilepsy. Eur J Paediatr Neurol 2012;16:15-19.
14. Rastogi RG, Ng Y. Lacosamide in refractory mixed pediatric epilepsy: a prospective add-on study. J Child Neurol 2010;27:492-5.
15. Casas-Fernández C, Martínez-Bermejo A, Rufo-Campos M et al. Efficacy and tolerability of lacosamide in the concomitant treatment of 130 patients under 16 years of age with refractory epilepsy: a prospective, open-label, observational, multicenter study in Spain. Drugs R D 2012;12:187-97.
16. Verrotti A, Loiacono G, Pizzolorusso A et al. Lacosamide in pediatric and adult patients: comparison of efficacy and safety. Seizure 2013;22:210-6.
17. Novy J, Bartolini E, Bell GS, Duncan JS, Sander JW. Long-term retention of lacosamide in a large cohort of people with medically refractory epilepsy: a single centre evaluation. Epilepsy Res 2013;106:250-6.
18. Hancock EC, Cross HH. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev 2009; 8: CD003277.
19. Lemmon ME, Kossoff EH. New treatment options for Lennox-Gastaut syndrome. Curr Treat Options Neurol 2013;15:519-28.
20. Crumrine P. Management of seizures in Lennox-Gastaut syndrome. Paediatr Drugs 2011;13:107-18.
21. Cuzzola A, Ferlazzo E, Italiano D, Calabrò RS, Bramanti P, Genton P. Does lacosamide aggravate Lennox-Gastaut syndrome? Report on three consecutive cases. Epilepsy Behav 2010;19:650-1.
22. Andrade-Machado R, Benjumea-Cuartas V, Jaramillo-Jimenez E. Lacosamide in Lennox-Gastaut syndrome: case report. Clin Neuropharmacol 2012;35:148-9.
23. Coppola G, Grosso S, Franzoni E et al. Rufinamide in children and adults with Lennox-Gastaut syndrome: first Italia multicenter experience. Seizure 2010;19:587-91.
24. Kim SH, Eun SH, Kang HC et al. Rufinamide as an adjuvant treatment in children with Lennox-Gastaut syndrome. Seizure 2012;21:288-91.
25. Buck ML, Goodkin HP. Use of lacosamide in children with refractory epilepsy. J Pediatr Pharmacol Ther 2012;17:211-9.